Digital Health Applications (DiGAs) in Germany
In our digital age, more and more apps are being developed that improve patient care. Called Digital Health Applications or “DiGAs” in Germany, these are evidence-based certified medical devices that support patients in their treatment and whose medical purpose is achieved through a digital technologies-based main function.
Manufacturers of DiGAs will be reimbursed by statutory health insurance companies in Germany if the digital health applications meet the requirements of laws and regulations such as the Digital Healthcare Act (DVG), the associated ordinance (Digital Health Applications Ordinance — DiGAV) and the Digital Act (DigiG), the latter of which only came into force on March 26, 2024.
All DiGAs that are provisionally or permanently listed in the DiGA directory maintained by the German drug and medical devices regulator BfArM become eligible for prescription and thus reimbursement. But to be listed a DiGA must first undergo a review procedure at the BfArM, the so-called “fast-track procedure”.
In addition to the technical and data protection requirements, § 10 of the DiGAV stipulates that clinical investigations must be conducted to demonstrate a so-called “positive care effect” of the DiGA. Positive care effects are either a medical benefit (e.g., improvement in quality of life, prolongation of survival, or shortening of the duration of illness) or patient-relevant structural and procedural improvements in care. In the case of structural and procedural improvements, DiGA aims to support the actions of patients or to integrate processes between patients and service providers. For example, Digital Health Applications can be used to support patients in coping with illness-related difficulties in everyday life or in the coordination of treatment processes. Treatment adherence, patient safety, patient sovereignty, and health literacy are other areas that can be achieved or supported with the help of digital health applications.
According to the German Social Code (SGB) — Fifth Book (V) § 139e clause 4, the scientific evaluation concept to be submitted as part of the fast-track procedure has to be prepared by a manufacturer-independent institute to demonstrate the positive care effect. As a contract research organization and consultancy with many years of experience, we are happy to do this for you.
Leave A Comment